Trial Profile
A pragmatic, non-randomized, non-inferiority study of evaluating efficacy and costs of Adalimumab treatment in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients: Ingebio Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Jul 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- 01 Jul 2017 New trial record
- 17 Jun 2017 Preliminary results presented at the 18th Annual Congress of the European League Against Rheumatism